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Available online 26 November 2015The Genea015 human embryonic stem cell line was derived from a donated, fully commercially consented
ART blastocyst, through ICM outgrowth on inactivated human feeders. The line showed pluripotent cell
morphology and genomic analysis veriﬁed a 46, XY karyotype and male Allele pattern through traditional
karyotyping, CGH and STR analysis. Pluripotency of Genea015 was demonstrated with 80% of cells express-
ing Nanog, 97% Oct4, 75% Tra1-60 and 98% SSEA4, a PluriTest Pluripotency score of 29.52, Novelty score of
1.3 and Alkaline Phosphatase activity. The cell line was negative for Mycoplasma and any visible
contamination.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Kstitution Genea Biocells
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dateJuly, 2007rigin Human embryos
ype of resource Derived human embryonic stem cell line
b-type Human pluripotent cell line
ey marker
expressionNanog, Oct4, Tra1-60, and SSEA4uthentication Identity and purity of cell line conﬁrmed (Figs. 1–2 and
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(Laurent et al., 2011)
http://www.ncbi.nlm.nih.gov/pubmed/?term=21211785formation in public
databasesNational Institutes of Health registered, NIH:
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GEO: GSM638420thical approval Obtained from the Genea Ethics Committee on 21
February 2001 under the Australian National Health and
Medical Research Council (NHMRC) licence 309703. This is an open access article underResource detailstheate of derivationCC BY-NC-ND license (June 2007
aryotype 46, XY — no abnormalities detected
x Male
luripotent YES — by Alkaline Phosphatase stain positivity, Nanog,
Oct4, Tra1-60 and SSEA4 staining and PluriTest
isease status Unaffected
erility The cell line is tested and found negative for Mycoplasma
and any visible contamination
bling lines available YES — GENEA016 (XX, NIH: NIHhESC-13-0229)SiMaterials and methods
Cell line derivation
The zona pellucida of a blastocyst-stage human embryo was
removed with pronase. The embryo was bisected and plated onto
mitomycin C inactivated Detroit 510 HFF (plated 200,000 cells per
organ culture dish - 69,204 cells/cm2) in 20% Knock out serum in
standard hESC culture medium (Amit et al., 2000) with 50 ng/ml
Fgf2. Karyotyping, CGH and DNA proﬁling were performed at the
ﬁrst cryobanking step from ICM outgrowths maintained on feeders.
Alkaline Phosphatase staining was performed on feeders. Cells were
then enzymatically passaged as single cells and karyotyping repeat-
ed, immunoﬂuorescent pluripotent marker staining, PluriTest and
sterility testing performed.http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Morphology and karyotype of Genea015. A) Brightﬁeld (passage 3) growing on
human inactivated feeders. B) Alkaline phosphatase activity (passage 21) on human
inactivated feeders. C) Karyotypic analysis (passage 5) showing 46, XY normal, male
karyotype.
Table 1
CGH analysis summary; Genea015 (passage 18, 2 enzymatic) reporting a male cell line
and no abnormalities detected.
CGH summary
Sample name Genea015p18_2
Date reported 20th August 2013
Hybridisation balance A balanced hybridization was observed for all
chromosomes, relative to reference DNA
Copy number change No copy number changes N400 kb were detected
Interpretation Male cell line — no abnormalities detected
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Karyotyping
Passage 5; for enrichment of metaphase cells, cellular outgrowths
were incubated with either 0.22 ng/ml colcemid (Invitrogen) and
37.5 g/ml BrdU (Sigma) for 17–19 h or 5 ng/ml colcemid for 2.5 h.
Single cells were subsequently obtained using Non-Enzymatic Cell Disso-
ciation Solution (Sigma) and transferred to Sydney IVF's (nowGenea) di-
agnostic cytogenetics laboratory for preparation of metaphase spreads
and cytogenetic analysis by G-banding. A minimum of 15 metaphase
cells were examined, of which a full karyotype or chromosome counts
was performed for 5 and 10 of the metaphases respectively.
Comparative Genomic Hybridisation (CGH) based chromosomal analysis
Passage 18 (16 on feeders, 2 enzymatic); CGH was used to screen
targeted regions of the genome for gains and losses associated with
chromosomal imbalances such as aneuploidy, deletions and duplica-
tions. CGHwas performed using SurePrint G3microarrays (8× 60K for-
mat) which were scanned with the Agilent Scanner C and analysed
using Genomic Workbench Standard Edition 5.0 software (Agilent
Technologies).
DNA proﬁling
Passage 18 (16 on feeders, 2 enymatic); DNA ‘ﬁngerprinting’
was performed using the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit
(Applied Biosystems #4322288) to provide permanent genetic identiﬁ-
cation of the cell lines. https://www.thermoﬁsher.com/order/catalog/
product/4322288.
Pluripotency assessment
Alkaline Phosphatase
Passage p21; Genea015 was stained as per manufacturer's protocol
using theMerckMillipore Alkaline Phosphatase Detection Kit (SCR004).
Immunoﬂuorescence
Passage 18 (16 on feeders, 2 enzymatic); cells were ﬁxed with for-
malin and stained with Nanog #560483 1:200; Oct4 #560217 1:150:
Tra1-60 #560121 1:150; SSEA4 #560308 1:200 (all BD Pharmingen).
Images were acquired with an IN Cell Analyser 6000 and quantiﬁed
using In Cell Developer Software (GE).
PluriTest
Passage 18 (16 on feeders, 2 enzymatic); RNAwas collected and sub-
jected to a PluriTest, a bioinformatic assay of pluripotency in human
cells based on gene expression proﬁles (Müller et al., 2012).
Sterility testing
Mycoplasma
Passage 27; testing was performed at the Victorian Infectious
Diseases Reference Laboratory using Mycoplasma Genus PCR.
Microbial contamination
Testing was performed in conjunction with our QC measures. Cells
were thawed and cultured in 7 ml antibiotic free medium (Genea
Biocells M2 medium) for 2–3 days at 37 °C. A clear solution at ~48–
72 h indicated lack of bacterial, fungal or yeast contamination. Clarity
of the solution was assessed by Cell Production Team.
Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘Development of human embryonic
stem cells from excess ART embryos’) was obtained from the Genea
Ethics Committee on 21 February, 2001. Excess ART embryos werefully consented for stem cell derivation by all responsible people
through an informed consent process (signed de-identiﬁed consent
form can be provided upon request). Donors have received no payment
or ﬁnancial beneﬁts for their donation. Genea015 has been derived from
a donated, fully commercially consented human embryo, originally
created by assisted reproduction technology (ART) for the purpose of
procreation, under Australian National Health and Medical Research
Council (NHMRC) licence 309703. This licence was issued to GENEA
on 16 April, 2004. More information about the licence can be obtained
from the NHMRC webpage at http://www.nhmrc.gov.au/health-
ethics/human-embryos-and-cloning/database-licences-authorising-use-
excess-art-embryos.
Table 2
STR proﬁle; Genea015 (passage 18, 2 enzymatic), demonstrating male Allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317 D16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
GENEA015p18_2 13, 14 29, 31.2 10, 11 10, 12 16, 19 6, 8 11, 12 10, 11 18, 23 15, 16.2 17 8, 12 14, 15 11, 13 21, 23
Fig. 2. Pluripotency validation of Genea015. A) Immunoﬂuorescent staining (10×) of pluripotent cell markers SSEA4 (green), Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 18,
2 enzymatic). B) Quantitation of expression of pluripotent markers. C) PluriTest pluripotency (left) and novelty (right) scores with Genea015 (passage 18, 2 enzymatic) outlined in black.
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The derived stem cell line, Genea015, morphologically displays
adherent monolayer of compact cells in well-deﬁned colonies with
high nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1A/B).
Genetic analysis
The cell line has been karyotyped, demonstrating a 46, XY karyotype
(Fig. 1C, Supplementary Fig. 1), consistent with CGH analysis (Table 1,
Supplementary Fig. 2) and original derivation. Analysis of STR markers
showed Allele pattern consistent with male genotype (Table 2, Supple-
mentary Fig. 3).
Disease status
Unaffected.
Pluripotency
GENEA015 is pluripotent by:
1. Alkaline Phosphatase stain positivity (Fig. 1B);
2. Immunoﬂuorescence with 80% Nanog positive, 97% Oct4, 75% Tra1-
60 and 98% SSEA4 (Fig. 2A, quantiﬁed in 2B).
3. PluriTest with a 29.52 Pluripotency score and 1.3 Novelty score
(Fig. 2C).Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 4).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2015.11.008.
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